Detect mitochondrial toxicity of novel therapeutics using Cyprotex’s mitochondrial biogenesis assay.
Cyprotex deliver consistent, high quality data with the flexibility to adapt protocols based on specific customer requirements.
Mitochondrial biogenesis assay using HCS
Mitochondrial proteins are encoded by both mitochondrial and nuclear genomes. Mitochondrial biogenesis is defined as the growth and division of pre-existing mitochondria.1 Certain drugs are able to affect mitochondrial biogenesis through inhibition of mtDNA replication or mitochondrial encoded protein synthesis.
There is certain similarity between mitochondrial biogenesis and bacterial and viral replication. As a consequence, many antobacterial and antiviral agents cause mitochondrial toxicity through effects on human mitochondrial biogenesis. In fact, the FDA suggest that all antiviral drugs should be tested for effects on mitochondrial function.2
Cyprotex use high content screening and fluorescently labelled antibodies to evaluate ratios of an mtDNA-encoded protein (COX-1, a subunit of Complex IV) and an nDNA-encoded protein (SDH-A, a subunit of Complex II).
The mitochondrial biogenesis assay can be used to identify drugs cause toxicity through inhibition of mitochondrial biogenesis.
Mitochondria are the only organelles outside of the nucleus that contain their own genome and replicate itself in an independent manner from the nuclear genome
3Moreira AC et al, (2011), In: Biosensors for Health, Environment and Biosecurity, Serra PD (Ed.), 411-444
Mitochondrial biogenesis assay protocol
High content screening using fluorescently labelled antibodies for COX-1 and SDH-A
HepG2 or HepaRG (others available on request)
5-8 days depending on cell line and customer needs
Number of Concentrations
10 concentrations (n=3 wells per concentration)
COX-1 protein expression SDH-A protein expression COX-1/SDH-A protein expression ratio Cell loss
Data from Cyprotex's mitochondrial biogenesis assay
Cyprotex’s mitochondrial biogenesis assay uses high content imaging to detect COX-1 (mtDNA-encoded) and SDH-A (nDNA-encoded) protein expression. Using the ratio of COX-1/SDH-A protein expression, specific effects on mitochondrial biogenesis can be identified. The positive control for the assay, chloramphenicol (antibiotic), inhibits mitochondrial biogenesis in a dose-dependent manner (figure 1).
Figure 1 Dose curve for choramphenicol in the mitochondrial biogenesis assay
Figure 2A Dose curve for R1479 demonstrating the effect of the antiviral, R1479 (4’-azidocytidine) on mitochondrial biogenesis as illustrated by the impact on COX-1/SDH-A protein expression.
Figure 2B High content images illustrating the effect of increasing concentrations of R1479 (4'-azidocytidine) on COX-1/SDH-1 protein expression
1 Jornayvaz FR and Shulman GI (2010) Regulation of mitochondrial biogenesis. Essays Biochem47; 69-84 2 Food and Drug Administration. Guidance for Industry: Antiviral product development - Conducting and submitting virology studies to the agency (https://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/ UCM070953.pdf) 3 Moreira AC et al, (2011) Mitochondria as a biosensor for drug-induced toxicity - Is it really relevant? Biosensors for Health, Environment and Biosecurity, Serra PA (Ed.); 411-444